质子束放疗再照射治疗局部区域性复发非小细胞肺癌的多机构前瞻性研究
这项多机构前瞻性研究于2010年10月至2015年12月在三个质子中心纳入57例既往照射野内或附近复发的非小细胞肺癌患者,评估质子放疗再照射的安全性与可行性;52例(93%)完成再照射,1年总生存率和无进展生存率分别为59%和58%,24例(42%)发生≥3级急性和/或晚期毒性,结论为可行但可伴显著毒性。
要点
- 57例复发NSCLC患者接受质子再照射,52例(93%)完成疗程,中位年龄65岁(41-86)。
- 1年总生存率59%、无进展生存率58%;14例(25%)局部或区域复发,6例(11%)远处转移。
- 24例(42%)发生≥3级急性和/或晚期毒性,6例5级毒性;中心气道重叠增加、食管和心脏平均剂量增高及同步化疗与≥3级毒性显著相关。
核心结论
- 在这项前瞻性研究中,质子放疗用于复发性非小细胞肺癌再照射是可行的,但可伴随显著毒性。
- 提供者应谨慎进行非小细胞肺癌再照射,密切关注肿瘤体积、位置和相关剂量学参数。
- 需要进一步研究以优化患者选择、改善总体结局。
研究设计与样本
- 多机构前瞻性研究,2010年10月至2015年12月在三个质子中心纳入57例既往照射野内或附近复发的非小细胞肺癌患者。
- 患者按肿瘤体积、位置和临床特征分类;毒性采用美国国家癌症研究所不良事件通用术语标准4.0版评分;生存采用Kaplan-Meier分析。
主要发现
- 52例(93%)完成再照射疗程;中位年龄65岁(41-86)。
- 高肿瘤体积(临床靶区与内靶区比值≥250 cm3)患者因不可行于2012年8月停止入组;67%患者接受同步全身治疗。
- 14例(25%)出现局部(n=9)或区域(n=5)复发;再照射后6例(11%)发生远处转移。
- 1年总生存率和无进展生存率分别为59%和58%。
- 24例(42%)发生≥3级急性和/或晚期毒性,其中急性毒性22例(39%)、晚期毒性7例(12%);观察到6例5级毒性。
临床怎么用
- 作者认为质子放疗用于复发性非小细胞肺癌再照射是可行的但可伴显著毒性,提供者应谨慎进行再照射并密切关注肿瘤体积、位置和相关剂量学参数。
- 作者指出需要进一步研究以优化患者选择、改善总体结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The management of recurrent NSCLC in the setting of prior radiation therapy is challenging. Proton radiotherapy (PRT) is ideally suited to minimize toxicity to previously irradiated organs. We report the safety/feasibility of PRT for NSCLC reirradiation in a prospective multi-institutional study. MATERIALS AND METHODS: Between October 2010 and December 2015, 57 patients with recurrent NSCLC in or near their prior radiation field were treated at three proton centers. Patients were classified by tumor volume, location, and clinical characteristics. Toxicities were scored using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Survival outcomes were estimated by using Kaplan-Meier analysis. RESULTS: Fifty-two patients (93%) completed the reirradiation course. Their median age was 65 years (41-86). Patients with high tumor volume (clinical target volume-to-internal target volume ratio ≥250 cm3) were closed to enrollment owing to infeasibility in August 2012. Concurrent systemic therapy was delivered to 67% of patients. Fourteen patients (25%) had evidence of local (n = 9) or regional (n = 5) recurrence. Distant metastases after reirradiation developed in six patients (11%). The 1-year rates of overall and progression-free survival were 59% and 58%, respectively. In total, grade 3 or higher acute and/or late toxicity developed in 24 patients (42%), acute toxicity developed in 22 (39%), and late toxicity developed in seven (12%). Six grade 5 toxicities were observed. Increased overlap with the central airway region, mean esophagus and heart doses, and concurrent chemotherapy were associated with significantly higher rates of grade 3 or higher toxicity. Decreased overall survival was seen with increased mean esophagus dose (p = 0.007). CONCLUSIONS: In this prospective study, PRT for recurrent NSCLC is feasible but can be associated with significant toxicity. Providers should remain cautious in reirradiating NSCLC, paying close consideration to tumor volume, location, and relevant dosimetric parameters. Further research is needed for optimal patient selection to improve overall outcomes.
引用
- Chao HH, Berman AT, Simone CB, et al. Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. J Thorac Oncol. 2016. PMID: 27826034. doi:10.1016/j.jtho.2016.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。